Objective Direct hemoperfusion with polymyxin B-immobilized fiber columns (PMX-DHP) has been used for the treatment of septic shock. It was recently suggested that PMX-DHP may also be effective in acute exacerbations of idiopathic pulmonary fibrosis (IPF). However, all previous reports are case series without controls. The aim of the study was to determine the effects of PMX-DHP on the prognosis of the patients with rapidly progressive interstitial lung diseases (ILDs) in a case-control setting. Methods We herein retrospectively examined the clinical records of consecutive patients with acute exacerbation of IPF or rapidly progressive ILDs treated in our institute. We excluded those who had been treated with steroid pulse therapy for lung diseases, including those who had been taking more than 15 mg of oral prednisolone daily, or had undergone an operation within one month before the onset of acute respiratory failure. We compared the results of the laboratory tests and survivals between patients treated with and without PMX-DHP. Results Twenty-six patients were enrolled in the study. Among them, 13 patients were treated with PMX-DHP in addition to immunosuppressive therapy, including steroid pulse therapy. The mean survival time of patients treated with PMX-DHP tended to be longer than patients not treated with PXM-DHP (p=0.067). Six patients who underwent PMX-DHP on the first day of steroid pulse therapy had significantly longer survival times than those who were treated with standard medication alone (p<0.01). Conclusion These results suggest that PMX-DHP performed on the first day of steroid pulse therapy may improve the prognosis of patients with rapidly progressive ILDs.
Introduction
Direct hemoperfusion with polymyxin B-immobilized fiber column (PMX-DHP) which can effectively bind endotoxin is more effective than conventional therapy in patients with sepsis (1) . Acute respiratory distress syndrome (ARDS) is a condition involving bilateral pulmonary infiltrates and severe hypoxemia without evidence of cardiogenic pulmonary edema. Sepsis is one of the predisposing factors of ARDS and PMX-DHP is also effective for patients with ARDS (2-4). Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonia (5) . IPF has been recognized as a chronic, progressive, fibrotic lung disease with a median survival of approximately 3 years. Some patients with IPF experience acute respiratory deterioration without clinically apparent infection, left heart failure, pulmonary embolism, or other identifiable causes, which is known as acute exacerbations of IPF. An acute exacerbation of IPF histologically shares the tissue damage pattern of diffuse alveolar damage (DAD) with ARDS (6). Abe et al. reported that PMX-DHP might improve oxygenation and survival in IPF patients with acute exacerbation (7) . In addition, it was also effective in improving oxygenation and systemic inflammatory response syndrome in patients with rapidly progressive interstitial lung diseases (ILDs) (8) . However, all of the previous reports on the effects of PMX-DHP on acute exacerbations of IPF or rapidly progressive ILDs were case series without controls. In order to determine the effects of PMX-DHP on the prognosis of the patients with rapidly progressive ILDs, including acute exacerbations of IPF, we herein performed the first case-control study to date.
Materials and Methods

Study population
We retrospectively examined the clinical records of consecutive patients with acute exacerbations of IPF or rapidly progressive ILDs hospitalized and treated in the Niigata University Medical and Dental Hospital from 2005 to Aug 2012. An acute exacerbation of IPF was diagnosed as manifestation of all of the following: (i) development or unexplained worsening of dyspnea within 30 days, (ii) new superimposed ground-glass opacities in chest high resolution CT, (iii) a decrease in the PaO2 by 10 Torr or more, and (iv) an absence of an alternative explanation (such as infection, left heart failure, pulmonary embolism) or alternative causes of acute lung injury, such as trauma, blood infusion, or toxic inhalation. The criteria for the diagnosis of rapidly progressive ILDs were all the same as those of acute exacerbations of IPF except a P/F ratio <300 Torr was used instead of a decrease in the PaO2 by 10 Torr or more (9) . We excluded patients who had been treated with steroid pulse therapy for lung diseases, been taking more than 15 mg of oral prednisolone (PSL) daily, or undergone an operation within one month before the onset of acute respiratory failure. We collected the clinical data according to the Guidelines for Epidemiological Studies from The Ministry of Health, Labour and Welfare, Japan. The Committee of Ethics, Niigata University, approved the study protocol (2011, #1263).
Treatment
All of the patients were treated with systemic glucocorticoids, including high-dose intravenous ones [methylprednisolone (mPSL) 1 g daily for three days], followed by oral PSL at a dose of 1 mg/kg ideal body weight per day to a maximum daily dose of 60 mg. Since glucocorticoid treatment as a single agent is often not sufficient to improve ILDs and high-dose glucocorticoid therapy over a long period is often associated with severe side effects, we typically add one or two immunosuppressive drugs; however, the selection of the immunosuppressive drugs was empirical and arbitrary. We also occasionally added anticoagulation therapy because several reports have indicated that anticoagulation therapy is useful for ALI/ARDS (10-12).
PMX-DHP procedures
We administered hemoperfusion through an adsorbent column containing 5 mg of polymyxin B per gram of polystyrene fiber (Toraymyxin; Toray Industries, Tokyo, Japan) with the conventional equipment and a circuit for hemodialysis in addition to standard medical therapy. We inserted a double-lumen catheter into the femoral vein for venous access. Hemoperfusion using an adsorbent column with polymyxin B was performed at a flow rate of 80-100 mL/min for 3-24 hr. Each patient received 1-3 treatments with PMX-DHP with a time interval of approximately 24 hr. We administered nafamostat mesylates (Torii Pharma Co. Ltd., Tokyo, Japan) as the anticoagulant during hemoperfusion.
Statistical analysis
Comparisons of the categorical data were made with chisquare or Fisher's exact test. Nonparametric numeric data were compared by the Mann-Whitney U test. Kaplan-Meier survival curves were drawn for survival and were compared by means of a log-rank test. A p value <0.05 was considered to be statistically significant.
Results
Study participants
In total, 26 patients were enrolled in the study. We summarized the characteristics of our study population in Table 1. Collagen vascular diseases, such as underlying diseases, included rheumatoid arthritis (n=4), dermatomyositis (DM) (n=4), and undifferentiated connective tissue disease (n=4). Other diseases included acute interstitial pneumonia (n=2) and drug-induced pneumonia induced by tyrosine kinase inhibitors (n=2). Eight patients had been treated by oral PSL (12.5 mg daily or less). Cyclosporine was the immunosuppressant administered to keep the trough levels at 100 to 150 ng/mL. Intravenous cyclophosphamide (500 mg/ body) was empirically added to the PSL and cyclosporine. Only 3 patients had not received anticoagulants during the treatment courses.
Comparison between PMX-DHP and conventional therapy
Among the subjects, 13 were treated with PMX-DHP in addition to standard immunosuppressive therapy, including high-dose intravenous glucocorticoids. We divided the patients into two groups, those who were treated with PMX-DHP and those who were not. Although the classifications of underlying diseases were not matched, the CRP, KL-6, mean P/F ratios before glucocorticoid treatment, immunosuppressant, or anticoagulants were not statistically different between the two groups ( Table 2 ). The mean survival time of patients treated with PMX-DHP tended to be longer than that of those who were treated by standard therapy (p= 0.067, Fig. 1 ). Among the dead, two patients, one with IPF and one with Sjögren's syndrome and rheumatoid arthritis, had survived for longer than 100 days. Both of them showed improvement following steroid pulse therapy with or without PMX, but their respiratory functions gradually decreased during tapering of PSL resulting in fatal respiratory failure.
Comparison between PMX-DHP with pulse therapy and conventional therapy
In 13 patients treated with PMX-DHP, the treatment was administered on various hospital days: 6 patients underwent PMX-DHP on the first day of pulse therapy while the other patients underwent PMX-DHP on the third to sixth day following the initial high-dose glucocorticoid therapy. Comparisons of the laboratory data and P/F ratios before PMX-DHP administration and details of the PMX-DHP procedures are shown in Table 3 . In order to see the best administration time for PMX-DHP, we compared the survival curve of patients who underwent PMX-DHP on the first day of steroid pulse therapy with patients who received PMX-DHP at other times. Although we found no differences in the cycles and duration of the PMX-DHP treatment (Table 3), the two survival curves looked separate and the curve of patients who underwent PMX-DHP later was similar to that of the patients treated by standard immunosuppressive therapy only (Fig. 2) . Therefore, we then compared the sur- Figure 2 . The Kaplan-Meier curves for survival for the patients who underwent PMX-DHP were divided according to the timing of the PMX-DHP administration. Six patients who underwent PMX-DHP simultaneously with high-dose intravenous glucocorticoids (pulse therapy) had significantly longer survival times than those who had been treated with immunosuppressants alone (p<0.01). PMX/Pulse, PMX-DHP was performed on the first day of a steroid pulse therapy, intravenous methylprednisolone 1 g/day for 3 days; Pulse PMX, PMX-DHP was added to a steroid pulse therapy two to six days later. vival curves between those who underwent PMX-DHP simultaneously with steroid pulse therapy and the patients who did not receive PMX-DHP. The former group was male dominant, had a higher frequency of IPF as an underlying disease, and included no patients treated by the triple therapy of glucocorticoids, cyclosporine, and intravenous cyclophosphamide. The CRP, KL-6, and mean P/F ratios before PMX-DHP administration did not show any statistical differences (Table 4) . Although the demographics of these groups were not matched, the former had a significantly longer survival time than those who had been treated with medication alone (Fig. 2, p<0 .01).
Discussion
We herein retrospectively examined the clinical records of 26 consecutive patients with acute exacerbations of IPF or rapidly progressive ILDs. The mean survival time of patients treated with PMX-DHP tended to be longer than patients who did not receive PMX-DHP. Six patients who had undergone PMX-DHP on the first day of steroid pulse therapy had significantly longer survival times than those who had only received the standard immunosuppressive therapy.
The polymyxin B fiber column is an extracorporeal technique to effectively reduce blood endotoxin levels during sepsis. The addition of polymyxin B hemoperfusion to conventional therapy reduced mortality in a population with severe sepsis and/or septic shock due to intra-abdominal Gram-negative infections (1). Sepsis, a serious and widespread infection of the bloodstream, is the most common cause of ARDS. PMX-DHP improved the circulatory disturbance, oxygenation, and mortality in patients with ARDS (2, 3). The pathology associated with ARDS is diffuse alveolar damage (DAD), which is characterized by a diffuse inflammation of the lung parenchyma. DAD superimposed on the typical underlying usual interstitial pneumonia pattern is the most commonly described finding in surgically biopsied lung specimens of patients with acute exacerbations of IPF (6). Seo et al. were the first to apply PMX-DHP to the treatment of acute exacerbations of IPF. They successfully treated 4 of 6 patients through administration of PMX-DHP in addition to glucocorticoid therapy (13). Abe et al. suggested that PMX-DHP might improve oxygenation and survival in IPF patients with acute exacerbation following a study of a large and diverse cohort treated with PMX-DHP (7).
Amyopathic DM (ADM), a distinct subgroup of DM with the characteristic skin rash and no or little muscle weakness, sometimes develops rapidly progressive ILD, which is often resistant to intensive therapy, including high-dose glucocorticoids and immunosuppressive agents (14) . Pathologically, DAD is also evident in rapidly progressive ILD associated with ADM (15, 16) . A novel autoantibody, anti-CADM-140, was identified and patients with the antibody frequently had ADM with rapidly progressive ILD (17). Teruya et al. described an ADM patient who developed rapidly progressive ILD with elevated anti-CADM-140 autoantibody was successfully treated with PMX-DHP after being resistant to combined steroid and immunosuppressant therapy (18) . Hara et al. reported that PMX-DHP would be a safe and effective therapy for rapidly progressive ILDs of different etiologies that were resistant to initial high-dose glucocorticoid therapy (8) . In addition, Sato et al. reported that a patient with severe amiodarone pulmonary toxicity was successfully treated with PMX-DHP and completely recovered (19) . In that case, the patient's severe respiratory failure improved with the reduction of amiodarone and monodesethylamiodarone serum levels by PMX-DHP (19) .
We typically treat patients with an acute exacerbation of IPF with broad-spectrum antibiotics and high-dose glucocorticoids, but the scientific evidence for this is lacking. Although various reports on the effects of PMX-DHP on acute exacerbations of IPF or rapidly progressive ILDs are in the literature, all of them were observational studies without controls. Evidence-based medicine is the care of patients using the best available research evidence to guide the clinical decision-making process (20) . The best evidence is obtained from properly designed randomized controlled trials, but because the disease incidence is too low for proper randomization, the effects of PMX-DHP on acute exacerbations of IPF may be difficult to test. Our report is the first case-control study on the effects of PMX-DHP on rapidly progressive ILDs including acute exacerbations of IPF. In order to obtain better evidence for this treatment, a cohort or casecontrol analytic study needs to be conducted, preferably from more than one center or research group. Furthermore, a prospective study with predetermined eligibility criteria and outcome measures should be designed.
Although the mechanisms by which PMX-DHP improves oxygenation in rapidly progressive ILD or acute exacerbations of IPF are unclear, various circulating molecules (i.e., monocyte chemotactic protein 1, metalloproteinase (MMP) -9, tissue inhibitor of MMP-1, neutrophil elastase, and IL-8) were decreased by the treatment (3, 8, 21) . Oishi et al. reported that the serum levels of cytokines, IL-9, IL-12, IL-17, PDGF, and VEGF significantly decreased immediately after PMX-DHP (22) . Additionally, inflammatory cells, in particular activated monocytes, producing such mediators may be removed by PMX treatment (23, 24) . These results suggest that removal of proinflammatory, profibrotic, and proangiogenic cytokines by PMX-fibers may improve oxygenation in those patients. If the removal of these molecules were delayed, acute lung injury would progress into irreversible fibrosis resulting in fatal respiratory failure. This hypothesis may be supported by the improved prognosis seen in patients treated with the simultaneous administration of PMX-DHP with steroid pulse therapy.
There are some limitations associated with our study. The sample number is small. Underlying diseases between the PMX and conventional therapy groups were not matched. Gender, underlying diseases, and medication between the PMX/Pulse and conventional therapy groups were also not matched. The former had more IPF and no patients were treated with triple therapy (e.g., glucocorticoids, cyclosporine, and intravenous cyclophosphamide). Further studies enrolling a larger cohort with matched treatment groups are necessary to confirm the effects of PMX-DHP on rapidly progressive ILD or acute exacerbations of IPF.
In conclusion, we herein retrospectively examined the clinical records of 26 consecutive patients with rapidly progressive ILD including acute exacerbations of IPF. The patients treated with PMX-DHP had a longer survival time compared with those who received the standard treatment. Although the demographics of the patients were not matched, six patients who had undergone PMX-DHP simultaneously with steroid pulse therapy had significantly longer survival times. In order to confirm this effect, further prospective studies with predetermined eligibility criteria and outcome measures are necessary.
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